This protocol addresses patients with mycosis fungoides at clinical stage IA, IB, or IIA — the early-stage disease spectrum. Evidence supporting this scenario includes comparative data from studies with histologically confirmed early-stage MF across stages IA, IB, and IIA.
In early-stage disease that is refractory to skin-directed therapy, systemic treatment options and certain radiotherapy modalities are considered — including agents selected according to specific disease characteristics. The full structured regimen with selection criteria and sequencing is available via the link below.
DOI: 10.1016/j.ejca.2023.113343